Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Advances in Microarray Technology

's Biography



, ,

Larry Gold is the founder, Chairman of the Board, and Chief Executive Officer of SomaLogic. Prior to SomaLogic, he also founded NeXagen, Inc., which later became NeXstar Pharmaceuticals, Inc. In 1999, NeXstar merged with Gilead Sciences, Inc. to form a global organization committed to the discovery, development and commercialization of novel products that treat infectious diseases. During nearly 10 years at NeXstar, Dr. Gold held numerous executive positions including Chairman of the Board, Executive VP of R&D, and Chief Science Officer. Before forming NeXagen, he also co-founded and served as co-Director of Research at Synergen, Inc., a pioneering biotechnology company later acquired by Amgen, Inc. Since 1970, Dr. Gold has been a professor at the University of Colorado at Boulder (CU). While at the university, he served as the chairman of the Molecular, Cellular and Developmental Biology Department from 1988 to 1992. During his prestigious career, Dr. Gold has received many citations including the CU Distinguished Lectureship Award, the National Institutes of Health Merit Award, the Career Development Award, and the Chiron Prize for Biotechnology. In addition, Dr. Gold has been a member of the American Academy of Arts and Sciences since 1993 and the National Academy of Sciences since 1995. Dr. Gold also serves on the board of directors of Complegen, MicroPhage, and Plato BioPharma

  Image

Proteomics at High Content using DNA Microarray Technology

Friday, 1 July 2011 at 10:00

Add to Calendar ▼2011-07-01 10:00:002011-07-01 11:00:00Europe/LondonProteomics at High Content using DNA Microarray TechnologySELECTBIOenquiries@selectbiosciences.com

We have been able to create a new class of aptamers, called SOMAmers, in which binding specificity for the intended human proteins is remarkably high (equivalent to the pair of antibodies in an ELISA), and we have been able to develop an assay format in which the SOMAmers that bind to their cognate targets are quantified using DNA microarray technology (or QPCR). In the present version of the assay, inspecting about 1,100 human proteins, we use roughly 15 ml of any complex sample (without depletions of any kind) to determine the concentrations of each protein in the sample. A description of the proteomics assay and a review of SomaLogic’s clinical pipeline will be provided.


Add to Calendar ▼2011-06-30 00:00:002011-07-01 00:00:00Europe/LondonAdvances in Microarray TechnologySELECTBIOenquiries@selectbiosciences.com